SOUTH SAN FRANCISCO, Calif.,
Oct. 19, 2017 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. (NASDAQ:TTNP) announced today the planned
presentation of non-clinical data on the use of its ProNeura™
subdermal implant for the long-term, sustained delivery of
liothyronine (L-T3) during a poster session on Oct. 20 at the 87th annual conference of the
American Thyroid Association in Victoria,
British Columbia, Canada. The data indicate that these
ProNeura implants continuously released L-T3 dose dependently for
more than six months, providing important initial in vivo
information for the potential development as a treatment of
hypothyroidism.
While treatment of hypothyroidism with daily oral levothyroxine
(L-T4) alone is effective in most hypothyroid patients, about 15
percent report feeling inadequately treated and are often
prescribed a combination of L-T3 with L-T4. A sustained release
L-T3 formulation could be an important alternative to combination
therapy, as compliance with multiple daily dosing regimens can be
challenging.
"We are encouraged by these initial, non-clinical data
demonstrating the successful delivery of L-T3 with our ProNeura
continuous, long-term drug delivery platform," said Titan Executive
Vice President and Chief Development Officer Kate Beebe, PhD. "The results merit further
studies to evaluate the potential therapeutic substitution of, or
combination with L-T4 for the treatment of hypothyroidism.
Additional discussions with endocrinology experts are needed to
continue assessment of the product development and regulatory
pathways, as well as to further evaluate the market opportunity and
potential for collaboration."
In these studies, ProNeura-based L-T3 implants were formulated
and tested for release characteristics in several non-clinical
models. Pharmacokinetics of T3, T4, and TSH levels were assessed
for varying implant doses in serum samples taken pre- and
post-implantation. Results showed these L-T3 implants continuously
released non-fluctuating levels of T3 dose dependently for over 6
months. The full poster will be available in the publications
section of the Titan website following the presentation.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc.
(NASDAQ:TTNP), based in South San
Francisco, CA, is developing proprietary therapeutics
primarily for the treatment of serious medical disorders. The
company's lead product is Probuphine®, a novel and long-acting
formulation of buprenorphine and the first and only commercialized
treatment of opioid dependence approved by the U.S. Food and Drug
Administration to provide continuous, around-the-clock blood levels
of buprenorphine for six months following a single procedure.
Probuphine employs Titan's proprietary drug delivery system
ProNeura™, which is capable of delivering sustained, consistent
levels of medication for three months or longer. Titan has granted
commercial rights in the U.S. and Canada for Probuphine to Braeburn
Pharmaceuticals. The ProNeura technology has the potential to be
used in developing products for treating other chronic conditions
such as Parkinson's disease and hypothyroidism, where maintaining
consistent, around-the-clock blood levels of medication may benefit
the patient and improve medical outcomes. For more information
about Titan, please visit www.titanpharm.com.
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACT:
Titan Pharmaceuticals, Inc.:
Sunil Bhonsle, President
(650) 244-4990
Investors:
Stephen Kilmer
(650) 989-2215
skilmer@titanpharm.com
Media:
Susan Thomas
(650) 989-2216
sthomas@titanpharm.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-presents-non-clinical-data-from-liothyronine-l-t3-implant-studies-300540250.html
SOURCE Titan Pharmaceuticals, Inc.